Vitamin E Dosage: What 400 IU Actually Means

Paid links: Some links in this article go to iHerb through an affiliate program: if you buy something after clicking one, StarterScience earns a commission and you pay the same price. That commission never changes how we describe the evidence, including when the evidence is weak. This article is general information, not medical advice — talk to a qualified healthcare professional before starting any supplement.

How this site is funded.

The Recommended Dietary Allowance for vitamin E is 15 mg a day for everyone aged 14 and over. The bottle on the shelf almost certainly says 400 IU. Those numbers look unrelated because they are written in different units, and the conversion is not intuitive: 400 IU of natural vitamin E is 268 mg of alpha-tocopherol — roughly eighteen times the RDA.

That gap is the entire vitamin E dosing story. What the body needs is small, comes mostly from cooking oil and nuts, and deficiency is genuinely rare. What is sold in softgels is a pharmacological dose — tested on well over 100,000 people in randomized trials, mostly returning nothing, with several findings pointing the wrong way. So instead of a benefits list: the label arithmetic, the two upper limits regulators have set (they disagree sharply), what the large trials of 400 IU found, and the narrow cases where a high dose is still defensible.

Start with the units, because that is where the label misleads

The Food and Nutrition Board's recommendations are for alpha-tocopherol alone — as the NIH Office of Dietary Supplements puts it, "the only form maintained in plasma." Here is what is actually recommended:

Infant values are Adequate Intakes rather than RDAs. Note that pregnancy does not raise the requirement at all; breastfeeding raises it by 4 mg.

US labels have listed vitamin E in milligrams since January 2020 (smaller manufacturers had until January 2021), but IU still appears on older stock and imported products. The ODS conversions:

• 1 IU of the natural form (RRR-alpha-tocopherol, labelled d-alpha-tocopherol) = 0.67 mg
• 1 IU of the synthetic form (all-rac-alpha-tocopherol, labelled dl-alpha-tocopherol) = 0.45 mg
• Going the other way: 1 mg alpha-tocopherol = 1.49 IU natural or 2.22 IU synthetic, so 15 mg is 22.4 IU of the natural form or 33.3 IU of the synthetic one

So two bottles both reading "400 IU" can differ by 88 mg of actual alpha-tocopherol depending on the form inside. Milligram for milligram the synthetic form counts for half as much: the ODS states that 1 mg of vitamin E equals 1 mg RRR-alpha-tocopherol or 2 mg all-rac-alpha-tocopherol.

What a capsule actually delivers, in RDA multiples

Applying those factors to shelf strengths gives the table nobody prints on a bottle. The last two columns compare the natural-form dose against the upper limits discussed next — 1,000 mg/day in the US, 300 mg/day in the EU.

The milligram figures for 400 IU are the ones the ODS itself uses (268 mg natural, 180 mg synthetic); the rest follow from the same conversion factors. A single 400 IU natural-form softgel is not "topping up" anything — it is nearly the entire European daily ceiling in one swallow. The 1999–2000 NHANES survey found 11.3% of US adults taking vitamin E supplements containing at least 400 IU.

Two regulators, two ceilings, threefold apart

Both upper limits are built on the same concern — vitamin E interferes with blood clotting — and they land in very different places.

United States. The Food and Nutrition Board's Tolerable Upper Intake Level is 1,000 mg/day for adults 19 and over (1,500 IU natural or 1,100 IU synthetic), 800 mg at 14–18 years, 600 mg at 9–13, 300 mg at 4–8, 200 mg at 1–3. Below age 1 there is no number at all: "Vitamin E ULs for infants have not been established." The ODS is also candid that the adult figure rests on thin data — those doses "appear to be safe, although the data are limited and based on small groups of people taking up to 3,200 mg/day of alpha-tocopherol for only a few weeks or months."

European Union. EFSA re-examined the question in 2024 and kept the much lower limits the Scientific Committee on Food had set in 2003, stating plainly that "no new evidence has been published that could improve the characterisation of a dose–response." Those retained limits are 300 mg/day for adults, including pregnant and lactating women; 100 mg/day for ages 1–3, 120 mg for 4–6, 160 mg for 7–10, 220 mg for 11–14, and 260 mg for 15–17. What EFSA did add in 2024 are infant limits the US does not have: 50 mg/day at 4–6 months and 60 mg/day at 7–11 months, derived by scaling the adult figure down by body weight.

The reference point behind all of this is older than either agency's current document. The SCF took blood clotting as the critical effect, identified a no-observed-adverse-effect level of 800 IU/day (540 mg/day) from a 1998 study by Meydani and colleagues, and concluded that "an uncertainty factor (UF) of 2 would adequately cover interindividual differences." Divide 540 by 2 and round: 300 mg. That is the whole derivation of the European ceiling, and EFSA left it standing in 2024 for lack of better data.

EFSA adds caveats that matter more than the numbers. The limits "do not apply to individuals receiving anticoagulant or antiplatelet medications (e.g. aspirin), to patients on secondary prevention for CVD or to patients with vitamin K malabsorption syndromes," and — in the other direction — "ULs do not apply either to patients with specific conditions causing vitamin E deficiency." That second exclusion is why people with abetalipoproteinemia or AVED are prescribed doses many times the ceiling: the ceiling was never written for them. Either way, EFSA notes, "these population groups are under medical care, and hence, any vitamin E (α-tocopherol) supplementation should be under medical supervision."

What happened when 400 IU was tested on tens of thousands of people

Vitamin E is unusual among supplements: the popular dose has been run through several very large, long, placebo-controlled trials, and the results are not ambiguous.

Cardiovascular disease

The HOPE trial and its HOPE-TOO extension followed patients aged 55 and over with vascular disease or diabetes on 400 IU/day of natural-source vitamin E, with a median follow-up of 7.0 years. Among all HOPE patients, major cardiovascular events numbered 1,022 (21.5%) on vitamin E versus 985 (20.6%) on placebo, relative risk 1.04 (95% CI 0.96–1.14, P = .34). Cancer incidence was also flat. What the trial did find was a higher risk of heart failure in the vitamin E group (RR 1.13, 95% CI 1.01–1.26, P = .03) and of hospitalisation for heart failure (RR 1.21, 95% CI 1.00–1.47, P = .045); the same pattern held among patients at the centres that carried on into HOPE-TOO. The investigators' conclusion: long-term supplementation "does not prevent cancer or major cardiovascular events and may increase the risk for heart failure."

The Physicians' Health Study II randomised 14,641 male physicians aged 50 and over to 400 IU of synthetic alpha-tocopherol every other day for a mean of 8 years. Major cardiovascular events: hazard ratio 1.01 (95% CI 0.90–1.13, P = .86). Myocardial infarction, stroke, cardiovascular death, total mortality — all null. One result was not: there were 39 haemorrhagic strokes on vitamin E against 23 on placebo, HR 1.74 (95% CI 1.04–2.91, P = .036).

Prostate cancer

SELECT randomised 35,533 men to 400 IU/day of synthetic vitamin E (all-rac-alpha-tocopheryl acetate), selenium, both, or placebo. It was designed to show prevention. With longer follow-up, 620 men in the vitamin E arm developed prostate cancer versus 529 on placebo — hazard ratio 1.17 (99% CI 1.004–1.36, P = .008), an absolute increase of 1.6 cases per 1,000 person-years. The published conclusion is one sentence: "Dietary supplementation with vitamin E significantly increased the risk of prostate cancer among healthy men."

The absolute effect is small and has been contested since. But it remains the largest randomized test of exactly the dose sitting on the shelf, and it moved in the wrong direction.

Total mortality

A 2005 dose-response meta-analysis of 19 trials and 135,967 participants found that 9 of 11 trials of high-dose vitamin E (≥400 IU/day) showed increased all-cause mortality, pooled risk difference 39 deaths per 10,000 persons (95% CI 3 to 74, P = 0.035), with a significant dose-response above 150 IU/day. Its conclusion: high-dosage supplements "may increase all-cause mortality and should be avoided." The 2012 Cochrane review of antioxidant supplements pooled 78 trials and 296,707 participants; in the 56 trials at low risk of bias, antioxidants increased mortality (RR 1.04, 95% CI 1.01–1.07), with the vitamin E estimate at RR 1.03 (95% CI 1.00–1.05) across 46 trials.

That mortality signal is weak, and the sources say so themselves. The vitamin E confidence interval touches 1.00. Across all 78 trials Cochrane's headline analysis found no significant effect of antioxidants on mortality in a random-effects model (RR 1.02, 95% CI 0.98–1.05); the harm appears in the fixed-effect model and in the low-risk-of-bias subset. The published Feedback attached to that review — from Hickey, Schuitemaker and colleagues — attacks the analysis rather than the arithmetic, arguing the vitamin conclusion "was only produced by statistical manipulation when the effects of selenium were excluded, and the number of statistical tests was not reported"; Cochrane's authors replied that their analyses were pre-planned. And the ODS notes that participants in these analyses were typically middle-aged or older with chronic disease, and that a review restricted to healthy people taking vitamin E for primary prevention "found no convincing evidence that the supplements increased mortality." The fair reading is not that vitamin E kills people: it is that after 300,000 randomized participants nobody has shown a survival benefit, and the pooled estimate sits slightly on the harmful side of neutral.

The narrow places where a high dose still has support

Steatotic liver disease (MASH/NASH)

This is the strongest case, and it is a treatment case, not a wellness one. In the PIVENS trial, 247 adults with biopsy-proven nonalcoholic steatohepatitis and without diabetes took 800 IU/day of vitamin E, pioglitazone, or placebo for 96 weeks. Histology improved in 43% on vitamin E versus 19% on placebo (P = 0.001); fibrosis scores did not (P = 0.24).

The 2023 AASLD practice guidance lists vitamin E (rrr-alpha) 800 IU daily for "NASH without T2DM or cirrhosis," notes "no proven benefit on fibrosis," and lists the potential side effects in the same table as "Hemorrhagic stroke, risk of prostate cancer?" Those risks, it says, "should be discussed with patients before initiation of long-term high-dose (eg, 800 IU daily) vitamin E therapy." A supervised decision for people with a liver biopsy — not a reason to buy 800 IU capsules because an ultrasound mentioned fatty liver.

Mild-to-moderate Alzheimer's disease

The TEAM-AD trial randomised 613 patients with mild-to-moderate Alzheimer's disease at 14 Veterans Affairs medical centres to 2,000 IU/day of alpha-tocopherol, memantine, both, or placebo. Two conditions attached to that result and rarely survive the retelling: every participant was already taking an acetylcholinesterase inhibitor, so this is add-on therapy rather than a standalone effect, and the VA population was overwhelmingly male — the authors list the small proportion of women as a limitation. Over a mean 2.27 years, scores on the ADCS-ADL functional inventory declined 3.15 units less than placebo (95% CI 0.92–5.39, adjusted P = .03) — a delay in clinical progression of about 19% per year, or roughly 6.2 months over the follow-up. Cognition did not improve; the benefit was functional.

The 2017 Cochrane review put that in context: no evidence alpha-tocopherol improves cognition in Alzheimer's disease (ADAS-Cog mean difference −1.81, 95% CI −3.75 to 0.13), and none that it prevents progression from mild cognitive impairment to dementia (RR 1.03, 95% CI 0.79–1.35). The one positive finding is functional, from a single trial, graded moderate quality — and 2,000 IU/day works out to 900 mg of synthetic or 1,340 mg of natural alpha-tocopherol: at or above the 1,000 mg US ceiling, and three to four and a half times the 300 mg EU one. Supervised clinical decision, not self-medication.

Advanced age-related macular degeneration

In the AREDS trial, people at high risk of advanced AMD cut their risk of progression by 25% over 5 years on a combination of 400 IU dl-alpha-tocopheryl acetate, 15 mg beta-carotene, 500 mg vitamin C, 80 mg zinc and 2 mg copper; AREDS2 confirmed that and similar formulations. The benefit belongs to the formula, not to vitamin E: two randomized trials of vitamin E outside that formula showed no protective effect on AMD, and the AREDS formulation had no effect on cataracts.

Popular claims that do not survive the trials

Skin and scars. The best-known controlled test used a split-scar design in 15 patients after skin cancer surgery. In 90% of cases topical vitamin E either had no effect on, or worsened, the cosmetic appearance of the scar, and 33% developed contact dermatitis; the authors concluded its use on surgical wounds "should be discouraged." A small study — but it is the direct test, and no comparable trial shows the opposite.

Immunity. A year-long randomized trial gave 200 IU/day to 617 nursing home residents aged 65 and over. On the primary measures the result was flat: "no statistically significant effect of vitamin E on incidence or number of days with infection for all, upper, or lower respiratory infections." A secondary measure did move — among those who completed the year, 65% on vitamin E versus 74% on placebo caught at least one respiratory infection (risk ratio 0.88, 95% CI 0.75–0.99, p = 0.036; 60% vs 68% counting everyone randomised). A post-hoc common-cold analysis also favoured vitamin E. The authors treated these as findings that merit further investigation, not as grounds to supplement, and the trial's stated conclusion is that 200 IU/day "did not have a statistically significant effect on lower respiratory tract infections in elderly nursing home residents."

Pregnancy. A Cochrane review of 21 trials and 22,129 women found no clear benefit on stillbirth, neonatal death, pre-eclampsia, preterm birth or fetal growth, but did find increased term prelabour rupture of membranes (RR 1.77, 95% CI 1.37–2.28) and self-reported abdominal pain (RR 1.66, 95% CI 1.16–2.37). The pregnancy RDA is 15 mg, the same as everyone else's, and there is no evidence base for exceeding it.

Who actually needs supplemental vitamin E

The ODS is blunt: frank deficiency is rare, and "overt deficiency symptoms have not been found in healthy people who obtain little vitamin E from their diets." Those who genuinely need supplementation are a short, medically identifiable list:

• Fat-malabsorption disorders — Crohn's disease, cystic fibrosis, or an inability to secrete bile into the gut. These patients sometimes need water-soluble forms such as tocopheryl polyethylene glycol-1000 succinate.
• Two rare inherited disorders — abetalipoproteinemia, needing roughly 100 mg/kg or 5–10 g per day, and ataxia with vitamin E deficiency (AVED), where large doses prevent loss of the ability to walk. Both are managed by specialists, and both are among the conditions EFSA explicitly exempts from its upper limits.
• Premature infants of very low birth weight (<1,500 g), where supplementation may reduce some complications but can also increase infection risk — a neonatology decision.

Real deficiency symptoms are neurological, not cosmetic: peripheral neuropathy, ataxia, skeletal myopathy, retinopathy and impaired immune response. Dry skin is not one of them.

Getting 15 mg from food is not difficult

Surveys put most Americans below the RDA on paper, but the ODS cautions those estimates are probably low because the fats added during cooking are often unaccounted for, and the Food and Nutrition Board suggests mean intakes among healthy adults are "probably higher than the RDA." An ounce of sunflower seeds (7.4 mg), a tablespoon of sunflower oil (5.6 mg) and half a cup of boiled spinach (1.9 mg) is 14.9 mg — a day's worth, before anything else on the plate. Nuts alone do not do it: an ounce of almonds plus that tablespoon of oil is 12.4 mg, about 83% of the RDA.

One caveat is real: the FNB warns that low-fat diets may provide insufficient amounts unless people deliberately increase nuts, seeds, fruits and vegetables. If that is you, a low-dose product is a reasonable hedge — but the useful dose is tens of milligrams, not hundreds. Sorting a catalogue of vitamin E products (paid link) by strength rather than by brand makes that obvious: nearly everything on the market is dosed for the 400 IU habit, not for the requirement.

Reading a vitamin E label without getting fooled

• d- versus dl-. d-alpha-tocopherol is natural (RRR); dl-alpha-tocopherol is synthetic (all-rac). Per IU, natural delivers about 1.5× more alpha-tocopherol — a "400 IU" natural product is 268 mg, a synthetic one 180 mg. Neither form is "better" in outcome trials (SELECT used synthetic, the AASLD guidance specifies rrr-alpha), but you need to know which you are holding to know your dose.
• "Mixed tocopherols" is a marketing claim, not a dosing standard. Most vitamin E in American diets is gamma-tocopherol from soybean, canola and corn oils, but every recommendation and every trial above concerns alpha-tocopherol alone, the form maintained in plasma. No RDA, no upper limit and no outcome trial tells you how much gamma- or delta-tocopherol to take.
• Take it with food containing fat. Vitamin E is fat-soluble and the gut requires fat to absorb it — which is exactly why fat-malabsorption conditions cause deficiency.

If you have decided a supplement makes sense, the honest instruction is to pick the lowest strength that meets your purpose. Across the vitamin E supplement range (paid link) low-dose options exist but are outnumbered, and if you prefer a food source to isolated alpha-tocopherol, wheat germ oil and similar whole-food products (paid link) sit in the same catalogue. We earn a commission either way, which is exactly why the evidence sections above say what they say.

When supplemental vitamin E is a bad idea

• Anticoagulants and antiplatelet drugs. Vitamin E inhibits platelet aggregation and antagonises vitamin K-dependent clotting factors, so with warfarin or similar drugs it raises bleeding risk, especially alongside low vitamin K intake. The ODS notes the amounts needed for clinically significant effects are unknown but probably exceed 400 IU/day, and EFSA's upper limits explicitly do not apply to this group.
• Smokers, at doses far below the ceilings. The bleeding risk is not confined to mega-doses. Of the two trials the ODS cites for increased haemorrhagic stroke, one gave Finnish male smokers just 50 mg/day for an average of six years — one-sixth of the EU limit and one-twentieth of the US one. The other was PHS II, where most participants were also taking aspirin, which the ODS reads as a sign that vitamin E tends to cause bleeding.
• Before planned surgery. Bleeding is the endpoint both upper limits were built on. Neither the ODS nor EFSA publishes a stop-date, and the American College of Surgeons does not name a number either — it lists vitamin E among supplements that "can affect blood clotting, increase your risks for internal bleeding, or interact with other drugs you are taking" and tells patients to fully inform the surgical team about everything they take. So the honest instruction is not a tidy "stop two weeks before": it is to disclose the dose at the pre-op appointment and ask the surgeon and anaesthetist when to stop.
• Infants and young children. The US has set no upper limit below age 1 at all; EFSA's are 50 mg/day at 4–6 months and 60 mg at 7–11 months, and 100 mg/day for ages 1–3 — small enough that an adult capsule is wildly out of range.
• Chemotherapy or radiotherapy. Oncologists generally advise against antioxidant supplements during treatment, on the reasoning that they may protect cancer cells from the oxidative damage the therapy is meant to cause.
• Simvastatin plus niacin. An antioxidant combination including vitamin E blunted the rise in HDL2 cholesterol in people on that regimen.
• Pregnancy. The requirement is 15 mg, supplementation above it showed no benefit in 21 trials, and two harms turned up instead.

The short version

1. Your target is 15 mg/day, 19 mg if breastfeeding, and food usually gets you there.
2. If a label shows IU, multiply by 0.67 (natural) or 0.45 (synthetic) to get milligrams before judging the dose.
3. 400 IU is not a maintenance dose. It is 18× the RDA in natural form, and it is the dose that failed to prevent heart disease or cancer and produced adverse signals for haemorrhagic stroke, heart failure and prostate cancer across trials of roughly 60,000 people.
4. 800 IU and up has a real evidence base in exactly two supervised situations — biopsy-proven MASH without diabetes or cirrhosis, and mild-to-moderate Alzheimer's on top of an acetylcholinesterase inhibitor — both a clinician's call, as is any dose at all if you take an anticoagulant or antiplatelet drug, smoke, are pregnant, are on cancer treatment, or have surgery scheduled.

References

1. Vitamin E: Fact Sheet for Health Professionals, NIH Office of Dietary Supplements, 2021
2. Scientific opinion on the tolerable upper intake level for vitamin E, EFSA Panel on Nutrition, Novel Foods and Food Allergens, EFSA Journal, 2024
3. Lonn E et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer (HOPE and HOPE-TOO), JAMA, 2005
4. Sesso HD et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II, JAMA, 2008
5. Klein EA et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 2011
6. Miller ER 3rd et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality, Annals of Internal Medicine, 2005
7. Bjelakovic G et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases, Cochrane Database of Systematic Reviews, 2012
8. Sanyal AJ et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS), New England Journal of Medicine, 2010
9. Rinella ME et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease, Hepatology, 2023
10. Dysken MW et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial, JAMA, 2014
11. Farina N et al. Vitamin E for Alzheimer's dementia and mild cognitive impairment, Cochrane Database of Systematic Reviews, 2017
12. Rumbold A et al. Vitamin E supplementation in pregnancy, Cochrane Database of Systematic Reviews, 2015
13. Meydani SN et al. Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial, JAMA, 2004
14. Baumann LS, Spencer J. The effects of topical vitamin E on the cosmetic appearance of scars, Dermatologic Surgery, 1999
15. Medication and Surgery: Before Your Operation, American College of Surgeons